Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:36 UTC |
---|
HMDB ID | HMDB0014393 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Cabergoline |
---|
Description | Cabergoline is only found in individuals that have used or taken this drug. It is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors. The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, alpha1,- and alpha2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. |
---|
Structure | [H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 |
---|
Synonyms | Value | Source |
---|
(8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | ChEBI | (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide | ChEBI | 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | ChEBI | 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | ChEBI | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea | ChEBI | Cabergolina | ChEBI | Cabergolinum | ChEBI | Cabaser | Kegg | Dostinex | Kegg | (8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | Generator | (8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | Generator | 1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | Generator | 1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | Generator | 1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | Generator | 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | Generator | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea | Generator | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea | Generator | 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate | HMDB | Cabaseril | HMDB | Galastop | HMDB | Cabergoline diphosphate | HMDB |
|
---|
Chemical Formula | C26H37N5O2 |
---|
Average Molecular Weight | 451.6043 |
---|
Monoisotopic Molecular Weight | 451.294725453 |
---|
IUPAC Name | 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea |
---|
Traditional Name | cabergoline |
---|
CAS Registry Number | 81409-90-7 |
---|
SMILES | [H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC |
---|
InChI Identifier | InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 |
---|
InChI Key | KORNTPPJEAJQIU-KJXAQDMKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Alkaloids and derivatives |
---|
Class | Ergoline and derivatives |
---|
Sub Class | Lysergic acids and derivatives |
---|
Direct Parent | Lysergic acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Lysergic acid or derivatives
- Indoloquinoline
- Benzoquinoline
- Quinoline-3-carboxamide
- Pyrroloquinoline
- Quinoline
- 3-alkylindole
- Indole
- Indole or derivatives
- Isoindole or derivatives
- 3-piperidinecarboxamide
- Piperidinecarboxamide
- N-acyl urea
- Aralkylamine
- Ureide
- Benzenoid
- Piperidine
- Dicarboximide
- Heteroaromatic compound
- Pyrrole
- Urea
- Tertiary amine
- Tertiary aliphatic amine
- Carbonic acid derivative
- Amino acid or derivatives
- Organoheterocyclic compound
- Azacycle
- Carboxylic acid derivative
- Organooxygen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Hydrocarbon derivative
- Carbonyl group
- Organic nitrogen compound
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 102 - 104 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.064 g/L | Not Available | LogP | 2.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3591.9 | Semi standard non polar | 33892256 | Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3762.4 | Standard non polar | 33892256 | Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4811.9 | Standard polar | 33892256 | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3481.4 | Semi standard non polar | 33892256 | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3966.9 | Standard non polar | 33892256 | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4859.9 | Standard polar | 33892256 | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3528.5 | Semi standard non polar | 33892256 | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3890.9 | Standard non polar | 33892256 | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4534.4 | Standard polar | 33892256 | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3785.1 | Semi standard non polar | 33892256 | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3964.5 | Standard non polar | 33892256 | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4830.0 | Standard polar | 33892256 | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3719.2 | Semi standard non polar | 33892256 | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4195.5 | Standard non polar | 33892256 | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4871.3 | Standard polar | 33892256 | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3900.0 | Semi standard non polar | 33892256 | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4279.6 | Standard non polar | 33892256 | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4562.9 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Cabergoline GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4u-9332300000-c399dad54a5ca1142e58 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Cabergoline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 10V, Positive-QTOF | splash10-0uk9-6612900000-09532480a6bc0ee23c8b | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 20V, Positive-QTOF | splash10-0006-9547200000-4408faaf3f5607911d33 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 40V, Positive-QTOF | splash10-0006-9230000000-e8bfe5d55836ee96fff9 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 10V, Negative-QTOF | splash10-0udi-4004900000-a2459baf72baf4f7d4c0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 20V, Negative-QTOF | splash10-0fml-8138900000-802be7d5b4ed6f5ea2ea | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 40V, Negative-QTOF | splash10-0006-9456000000-a805853927d5cdb1b2fa | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 10V, Positive-QTOF | splash10-0udi-0000900000-789dda3470f1d5d2b188 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 20V, Positive-QTOF | splash10-0zgi-3008900000-cefe7417b2ff493d14e7 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 40V, Positive-QTOF | splash10-0zfr-4549000000-ffec92d47b323b6e170c | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 10V, Negative-QTOF | splash10-0udi-0003900000-4c85bc032d2cb605ace4 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 20V, Negative-QTOF | splash10-004i-1209000000-00a4b086d755fec1cdd3 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cabergoline 40V, Negative-QTOF | splash10-052o-3069000000-6aeb0c0daa38a57cc470 | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
General References | - Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson's disease]. Neurologia. 2003 May;18(4):202-9. [PubMed:12721865 ]
- Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. [PubMed:15341508 ]
- Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. [PubMed:8951172 ]
- Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. [PubMed:15330687 ]
|
---|